Aggressive therapy for highly active lupus erythematosus;Aggressive Therapie von hochaktivem systemischem Lupus erythematosus

Acta Medica Austriaca

Volumn 23, Issue 4, 1996, Pages 129-133

  Graninger, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

cyclophosphamide; immunapheresis; plasmapheresis; systemic lupus erythematosus (SLE)

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISOLONE;

CARDIOVASCULAR DISEASE; DISEASE ACTIVITY; DRUG USE; HUMAN; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; PLASMAPHERESIS; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONG-TERM CARE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLASMAPHERESIS; PROGNOSIS; STEROIDS; TREATMENT OUTCOME;

EID: 0029952930     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Fessler BJ, Boumpas DT: Severe major organ involvement in SLE. Rheum Dis Clin North Am 1995;21:81-98.
2. Lawrence EC: Systemic lupus erythematosus and the lung. In: Systemic lupus erythematosus (Lahita RG, Ed.), John Wiley&Sons, New York, 1987, S. 691-708.
3. Pistiner M, Wallace DJ, Nessim S: Lupus erythematosus in the 1980s: A survey of 570 patients. Arthritis Rheum 1991;21:55-59.
4. Matthay RA, Schwarz MI, Petty TL: Pulmonary manifestations of SLE. Medicine (Baltimore) 1974;54:397-409.
5. Carette S, Macher AM, Nussbaum A: Severe acute pulmonary disease in patients with SLE. Semin Arthr Rheum 1984;14:52-59.
6. Bertoni M, Brugnolo F, Bertoni E, Salvadori M, Romagnani S, Emmi L: Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study. Scand J Rheumatol 1994;23:82-86.
7. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JK: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet l992;340:741-745.
8. Balletta M, Sabella D, Magri P, Sepe V, Stanziale P, Di Luccio R, Colucci G, Fuiano G: Cidosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 1992;99:10.
9. Thumb N, Horak W: Therapy with chlorambucil in progressive chronic polyarthritis. Wien Z Inn Med 1968;49:462-470.
10. Thumb N: Side effects in immunosuppressive therapy. Acta Med Austriaca 1975;2:134-140.
11. Sabbour MS, Osman LM: Comparison of chlorambucil, azathioprine und cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis. Br J Dermatol 1979;100:113-125.
12. McCune WJ, Golbus J, Zeldes W: Clinical and immunological effects of monthly administration of intravenous cyclophosphamide in severe SLE. N Engl J Med 1988;318:1423-1431.
13. Varkila K, Hurme M: The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: Inhibition of T-helper cell induction in vitro. Immunology 1983;48:433-438.
14. Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982;128:2453-2457.
15. Mountz JD, Mushinski JF, Smith HR: Modulation of c-myb transcription in autoimmune disease by cyclophosphamide. J Immunol 1985;135:2417-2422.
16. Fox DA, McCune WJ: Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20:265-299.
17. Chan TM, Li FK, Wong RW, Wong KL, Chan KW, Cheng IK: Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 1995;71:321-327.
18. Belmont HM, Storch M, Buyon J, Abramson S: New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995;4:104-108.
19. Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, Flis R, Pirani C, Appel GB: Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71-78.
20. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H: A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 1994;3:107-112.
21. Eiser AR, Grishman E, Dreznin S: Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis. Clin Nephrol 1993;40:155-159.
22. Lewis EJ, Hunsicker LG, Lan SP, Ronde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-1379.
23. Kahn MF: The treatment of lupus in the 1990s. Clin Exp Rheumatol 8 Suppl 1990;5:10.
24. Pablos JL, Gutierrez Millet V, Gomez Reino JJ: Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand J Rheumatol 1994;23:142-144.
25. Haga HJ, D'Cruz D, Asherson R, Hughes GR: Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992;51:885-888.
26. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only . Arthritis Rheum 1991;34:945-950.
27. Macro M, Le Gangneux E, Gallet E, Maragnes P, Galateau F, Loyau G: Severe lupus with infectious thyroiditis and lethal cardiomyopathy. Clin Exp Rheumatol 1995;13:99-102.
28. Sandrasegaran K, Clarke CW, Nagendran V: Sub-clinical systemic lupus erythematosus presenting with acute myocarditis. Postgrad Med J 1992;68:475-478.
29. Dickens P, Nicholls J, Lau CP: Acute hemorrhagic myocarditis in systemic lupus erythematosus. Heart Vessels 1992;7:104-106.
30. Fukuda M, Kamiyama Y, Kawahara K, Kawamura K, Mori T, Honda M: The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus. Eur J Pediatr 1994;153:167-170.
31. Eiser AR, Shanies HM: Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 1994;37:428-431.
32. Disla E, Rhim HR, Reddy A, Ramaprasad S, Taranta A: Reversible cardiogenic shock in a patient with lupus myocarditis. J Rheumatol 1993;20:2174-1995.
33. Groen H, Bootsma H, Postma DS, Kallenberg CG: Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide [see comments]. J Rheumatol 1993;20:1055-1057.
34. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG: Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
35. Marson P, Tenderini ML, Doria A, Rigoli AM, De Silvestro G: Combined plasma-exchange and immunosuppressive therapy for neurologic involvement of systemic lupus erythematosus. Recenti Prog Med 1994;85:72-73.
36. Taniguchi Y, Yorioka N, Okushin S, Oda H, Usui K, Yamakido M: Usefulness of immunoadsorption therapy for systemic lupus erythematosus associated with transverse myelitis. A case report. Int J Artif Organs 1995;18:799-801.
37. Doria A, Piccoli A, Vesco P, Vaccaro E, Marson P, De Silvestro G, Ossi E, Gambari P: Therapy of lupus nephritis. A two-year prospective study. Ann Med Interne Paris 1994;145:307-311.
38. Lombardo R, Cepparrone F, Di Pietro G, Franco C, Graziani G, Avanzi G: Plasma exchange in systemic lupus erythematosus. Experience in thirty-seven patients. Int J Artif Organs 16 Suppl 1993;5:177-179.
39. Zielinski C, Muller C, Smolen J: Use of plasmapheresis in therapy of systemic lupus erythematosus: a controlled study. Acta Med Austriaca 1988;15: 155-158.
40. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ: Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784-1794.
41. Hanly JG, Hong C, Zayed E, Jones JV, Jones E: Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995;4:457-463.
42. Dau PC, Callahan J, Parker R, Golbus J: Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 1991;18:270-276.
43. Lachin JM, Lan SP: Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study. Control Clin Trials 1992;13:62-79.
44. Lewis EJ, Hunsicker LG, Lan SPea: A contolled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1374-1379.
45. Euler HH, Schroeder JO, Zeuner RA, Teske E: A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial. Int J Artif Organs 1991;14:639-646.
46. Hiepe F, Wolbart K, Schossler W, Speer A, Montag T, Mielke F, Apostoloff E: Development of a DNA-adsorbent for the specific removal of anti-DNA autoantibodies in systemic lupus erythematosus (SLE). Biomater Artif Cells Artif Organs 1990;18:683-688.
47. Colburn KK, Gusewitch GA, Statian Pooprasert BS, Weisbart RH: Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus. Clin Rheumatol 1990;9:475-482.
48. Traeger J, Laville M, Serres PF, Cronenberger M, Thomas M, Rev MJ, Bourgeat C: A new device for specific extracorporeal immunoadsorption of anti-DNA antibodies. In vitro and in vivo results. Ann Med Interne Paris 143 Suppl 1992;1:9-12.
49. Suzuki K, Hara M, Harigai M, Ishizuka T, Hirose T, Matsuki Y, Kawaguchi Y, Kitani A, Kawagoe M, Nakamura H: Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 1991;34:1546-1552.
50. Schneider M, Berning T, Waldendorf M, Glaser J, Gerlach U: Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus. J Rheumatol 1990;17:900-907.
51. Suzuki K, Matsuki Y, Hidaka T, Kawaguchi Y, Kawakami M, Hino K, Nakamura H: Double filtration plasmapheresis in a patient with autoimmune hepatitis-systemic lupus erythematosus overlap. Intern Med 1993;32:725-729.
52. Erickson RW, Franklin WA, Emlen W: Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum 1994;24:114-123.
53. Suzuki K, Hara M, Ishizuka I, Hirose T, Harigai M, Kitani K, Kawagoe M, Nakamura H: Continuous anti-dsDNA antibody apheresis in systemic lupus erythematosus. Lancet 1990;336:753-754.
54. Gao CL, Li BA, Chen CZ, Yu YT, Yuan P, Song JC: Clinical trials of immunoadsorbent in systemic lupus erythematosus therapy. Artif Organs 1995; 19:468-469.
55. Sany J: Intravenous immunoglobulin therapy for rheumatic diseases. Curr Opin Rheumatol 1994;6:305-310.
56. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R: Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:163-168.
57. Jordan SC: Intravenous gamma-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 1989;53:S164-9.
58. Hubbell E: Pathophysiology of systemic lupus erythematosus for pheresis operators. J Clin Apheresis 1990;5:115-118.
59. Schroeder JO, Zeuner RA, Euler HH, Loffler H: High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol 1996;23:71-75.
60. Radhakrishnan J, Valeri A, Kunis C, Appel GB: Use of cyclosporin in lupus nephritis. Contrib Nephrol 1995;114:10.
61. Wilson K, Abeles M: A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:1674-1677.
62. Radhakrishnan J, Kunis CL, D'Agati V, Appel GB: Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994;42:147-154.
63. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J: Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994;37:551-558.
64. Mrowka C, Sieberth H, G: Cyclosporin A (CyA) in the treatment of systemic lupus erythematosus - A therapeutic alternative? Nieren Hochdruckkr 1995;24:697-701.
65. Rook AH, Wolfe JT: Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. J Clin Apheresis 1994;9:28-30.
66. Marmont AM: Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus? Lupus 1993;2:151-156.
67. Urowitz MB: Is "aggressive" therapy necessary for systemic lupus erythematosus? Rheum Dis Clin North Am 1993;19:263-270.
68. Klippel JH: Is aggressive therapy effective for lupus? Rheum Dis Clin North Am 1993;19:249-261.
69. Janwityanuchit S, Totemchokchyakarn K, Krachangwongchai K, Vatanasuk M: Infection in systemic lupus erythematosus. J Med Assoc Thai 1993;76:542-548.
70. Pohl MA, Lan SP, Berl T: Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 1991;114:924-929.